Monnet F P
Département de Psychiatrie, Université McGill, Montréal, Québec, Canada.
Presse Med. 1993 Feb 13;22(5):218-23.
Sigma ligands have been identified as psychotomimetic agents unrelated to opioids. A number of neuroleptics possess moderate to high affinity for sigma binding sites, raising the possibility that sigma receptors mediate some of the antipsychotic effects of neuroleptics. In addition, sigma binding sites have been reported to be reduced in the temporal cortex and in the hippocampus of schizophrenic patients. This hypothesis is further supported by the use of the sigma ligands rimcazole, BMY-14802 and remoxipride as effective antipsychotic agents. The present report, reviewing briefly the physiological effects of sigma ligands, suggests that their antipsychotic properties are related to modulation of NMDA receptors. Thus, the use of sigma ligands may provide further understanding of the pathophysiology of psychoses and open new avenues for their treatment.
西格玛配体已被确认为与阿片类药物无关的拟精神病药物。许多抗精神病药物对西格玛结合位点具有中度至高亲和力，这增加了西格玛受体介导抗精神病药物某些抗精神病作用的可能性。此外，据报道，精神分裂症患者颞叶皮质和海马中的西格玛结合位点减少。西格玛配体利姆卡唑、BMY - 14802和瑞莫必利作为有效的抗精神病药物的应用进一步支持了这一假说。本报告简要回顾了西格玛配体的生理效应，表明它们的抗精神病特性与N - 甲基 - D - 天冬氨酸（NMDA）受体的调节有关。因此，使用西格玛配体可能会进一步加深对精神病病理生理学的理解，并为其治疗开辟新途径。
